Analysis Questions Efficacy of 'Innovative' Alzheimer's Drugs

A new analysis suggests that 'innovative' Alzheimer's drugs do not significantly help, leading the British National Health Service (NHS) to currently refuse payment for them, with private therapy costing over 100,000 euros.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

vijesti-meBosnian1h ago

Analiza: "Inovativni" ljekovi protiv Alchajmera ne pomažu značajno

Britanska Nacionalna zdravstvena služba (NHS) trenutno neće plaćati ove ljekove, a privatna 18-omjesečna terapija koštala bi više od 100.000 eura. Ali čak i da imate novac, da li se isplati plaćati ih?

Read full article →

PERSPECTA

PERSPECTA

Analysis Questions Efficacy of 'Innovative' Alzheimer's Drugs

Sources

Analiza: "Inovativni" ljekovi protiv Alchajmera ne pomažu značajno

Related Stories

Senior Balloon Vendor Receives Medical and Material Aid

DOH: Haze from Navotas landfill fire may pose health risks to NCR

Latvian Scientists Develop Gentler Infertility Diagnosis Method

Giorgos Mylonakis Remains Intubated in Critical but Stable Condition

PERSPECTA